Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia.

× No keyword cloud information.

16 in total

1. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544

2. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors: Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal: J Natl Cancer Inst Date: 2011-06-13 Impact factor: 13.506

3. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

Authors: C Sebban; A Lefranc; L Perrier; P Moreau; D Espinouse; A Schmidt; L Kammoun; H Ghesquieres; C Ferlay; J O Bay; S Lissandre; D Pérol; M Michallet; P Quittet
Journal: Eur J Cancer Date: 2012-01-14 Impact factor: 9.162

4. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy.

Authors: Constantin Volovat; Oleg A Gladkov; Igor M Bondarenko; Steve Barash; Anton Buchner; Peter Bias; Liat Adar; Noa Avisar
Journal: Clin Breast Cancer Date: 2013-10-25 Impact factor: 3.225

5. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal: Clin Infect Dis Date: 2011-02-15 Impact factor: 9.079

6. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.

Authors: Shin Ahn; Yoon-Seon Lee; Yun-Hee Chun; In-Ho Kwon; Won Kim; Kyung Soo Lim; Tae Won Kim; Kyoo-Hyung Lee
Journal: Support Care Cancer Date: 2010-06-16 Impact factor: 3.603

7. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors: J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544

8. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA.

Authors: Alison Freifeld; Jayashri Sankaranarayanan; Fred Ullrich; Junfeng Sun
Journal: Support Care Cancer Date: 2007-10-18 Impact factor: 3.603

Review 9. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Authors: Nicole M Kuderer; David C Dale; Jeffrey Crawford; Gary H Lyman
Journal: J Clin Oncol Date: 2007-07-20 Impact factor: 44.544

Review 10. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.

Authors: Katy L Cooper; Jason Madan; Sophie Whyte; Matt D Stevenson; Ron L Akehurst
Journal: BMC Cancer Date: 2011-09-23 Impact factor: 4.430